Pfizer is set to cut jobs in Switzerland as part of a multi-year effort to lower expenses, as reported by Bloomberg.
According to information not yet made public, the company aims to cut staff from around 300 to 70.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The reduction follows a broader downgrading of the drug manufacturer’s Swiss operations.
In early December 2025, Pfizer’s Swiss country manager Sabine Bruckner was replaced by Rea Lal, who now heads the local business but with a “diminished mandate.”
Bruckner has moved to a different role.
Pfizer is pursuing a cost-reduction plan of more than $7bn by 2027, as it seeks to restore growth in the years following the pandemic.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataA spokesperson described in an email statement a “streamlining and realigning” of resources to minimise complexity.
Pfizer did not comment on specific numbers.
The job cuts come as the cpmpany steps up activity in the obesity treatment field, confirming a move into the sector via a licensing arrangement worth up to $2bn with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical.
YaoPharma will conduct an ongoing Phase I trial of YP05002 and provide Pfizer with an exclusive licence to further develop, manufacture and commercialise the therapy globally.
Pfizer was recently involved in a bidding war with Novo Nordisk to acquire New York-based obesity biotech Metsera.
Following consideration of rival bids from the pharma giants, Metsera has accepted Pfizer’s $10bn proposal.
The planned workforce reduction in Switzerland adds to a series of similar moves by other pharmaceutical groups in the country, where pharmaceuticals are the largest export sector.
In November 2025, Novartis stated that it would eliminate up to 550 jobs in Switzerland.
